Interobserver Interpretative Reproducibility of GOLDFISH, A First Generation Gold-Facilitated Autometallographic Bright Field In Situ Hybridization Assay for HER-2/neu Amplification in Invasive Mammary Carcinoma

2002 ◽  
Vol 26 (7) ◽  
pp. 908-913 ◽  
Author(s):  
Raymond Tubbs ◽  
Marek Skacel ◽  
James Pettay ◽  
Richard Powell ◽  
Jonathan Myles ◽  
...  
CytoJournal ◽  
2010 ◽  
Vol 7 ◽  
pp. 21 ◽  
Author(s):  
Elsa Beraki ◽  
Torill Sauer

During the last years, HER-2 status kits and protocols for chromogen visualization of hybridization signals have come on the market. The first generation using chromogen visualization used single color probes. The second generation, now emerging on the market, uses dual chromogen visualization. The aim of this study has been to test a new dual color chromogen kit (Ventana INFORM HER2 Dual Colour ISH Roche®) and compare the results with our in-house method(s). The material consisted primarily of cytological material from invasive breast carcinomas in 49 women. Dual SISH was done on all 49 cytological and histological specimens. The histological specimens were treated according to the manufacturer’s recommendations. The procedure was modified in several steps in order to adapt it to the cytological material. Hybridization failed in two cytological specimens. Dual SISH showed concordant results on cytological and histological material as to amplified/not amplified. The included cases had the same HER-2 expression in the invasive and the in situ components on histology. Four IDC showed HER-2 amplification (8.5%). Polysomy was found in two cases. All dual SISH results except for one concurred with the results of the in-house method(s) (1/47=2.1%). The dual SISH is suitable for cytological examination of HER-2 status. The protocol must be optimized for cytological material.


2014 ◽  
pp. 15-20
Author(s):  
Van Huy Tran ◽  
Thi Minh Thi Ha ◽  
Trung Nghia Van ◽  
Viet Nhan Nguyen ◽  
Phan Tuong Quynh Le ◽  
...  

Background: HER-2/neu is a predictive biomarker for treatment of gastric cancer using trastuzumab in combination with chemotherapy. This study aimed to evaluate the status of HER-2/neu gene amplification using fluorescence in situ hybridization (FISH) in gastric cancer. Patients and methods: thirty six gastric cancer patients were assessed HER-2/neu gene amplification by FISH using PathVysionTM HER-2 DNA Probe kit (including HER-2/neu probe and CEP-17 probe) with biopsy and surgical specimens. Results: The HER-2/neu gene amplification was observed in three cases (8.3%), the HER-2/neu gene amplification rate in Lauren’s intestinal-type and diffuse-type were 11.8% and 5.2%, respectively. Conclusion: We applied successfully FISH technique with gastric cancer tissue samples. This technique could be performed as routine test in gastric cancer in order to select patients that benefit from trastuzumab in combination with chemotherapy.


BMC Cancer ◽  
2009 ◽  
Vol 9 (1) ◽  
Author(s):  
Fabíola E Rosa ◽  
Sara M Silveira ◽  
Cássia GT Silveira ◽  
Nádia A Bérgamo ◽  
Francisco A Moraes Neto ◽  
...  

1991 ◽  
Vol 29 (7) ◽  
pp. 1308-1311 ◽  
Author(s):  
M P Meyer ◽  
C A Markiw ◽  
R R Matuscak ◽  
A Saker ◽  
K McIntyre-Seltman ◽  
...  

Cancer ◽  
2008 ◽  
Vol 114 (2) ◽  
pp. 134-140 ◽  
Author(s):  
Hitoshi Itoh ◽  
Yoko Miyajima ◽  
Shinobu Umemura ◽  
Robert Y. Osamura

Sign in / Sign up

Export Citation Format

Share Document